Current Neurology and Neuroscience Reports

, Volume 7, Issue 1, pp 63–70 | Cite as

Chronic inflammatory demyelinating polyneuropathies: Current treatment strategies

Article

Abstract

Chronic inflammatory demyelinating polyradiculopathy (CIDP), considered an immune-mediated disease, is likely under-recognized and under-treated due to its heterogeneous presentation and the limitations of clinical, serologic, and electrophysiologic diagnostic criteria. Despite these limitations, early diagnosis and treatment is important in preventing irreversible axonal loss and improving functional recovery. Primary treatment modalities include intravenous immunoglobulin and plasmapheresis, for which there is randomized, double-blind, placebo-controlled evidence. In addition, despite less definitive published evidence of efficacy, corticosteroids are considered standard therapies because of their long history of use. Studies have failed to demonstrate a difference in efficacy among these three treatments; consequently, the choice is usually based on availability and side-effect profile. A number of chemotherapeutic and immunosuppressive agents have also shown to be effective in treating CIDP but significant evidence is lacking; therefore, these agents are primarily used in conjunction with other modalities. Regardless of the treatment choice, long-term therapy is required to maintain a response and prevent relapse.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Dyck PJ, Lais AC, Ohta M, et al.: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975, 50:621–637.PubMedGoogle Scholar
  2. 2.
    Toyka KV, Gold R: The pathogenesis of CIDP, rational for treatment with immunomodulatory agents. Neurology 2003, 60(Suppl 3):S2–S7.PubMedGoogle Scholar
  3. 3.
    Koller H, Schroeter M, Kieseier BC, Hartung HP: Chronic inflammatory demyelinating polyneuropathy — update on pathogenesis, diagnostic criteria and therapy. Curr Opin Neurol 2005, 18:273–278.PubMedCrossRefGoogle Scholar
  4. 4.
    McLeod JG, Pollard JD, Macaskill P, et al.: Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999, 46:910–913.PubMedCrossRefGoogle Scholar
  5. 5.
    Mygland A, Monstadt P: Chronic polyneuropathies in Vest-Agder Norway. Eur J Neurol 2001, 8:157–165.PubMedCrossRefGoogle Scholar
  6. 6.
    Latov N: Diagnosis of CIDP. Neurology 2002, 59(Suppl 6):S2–S6.PubMedGoogle Scholar
  7. 7.
    Briani C, Brannagan TH, Trojaborg W, Latov N: Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord 1996, 6:311–325.PubMedCrossRefGoogle Scholar
  8. 8.
    Cornblath DR, Feasby TE, Hahn AF, et al.: Research criteria for diagnosis of chronic inflammatory demeyelianting polyneuropathy (CIDP). Neurology 1991, 41:617–618.Google Scholar
  9. 9.
    Hattori N, Misu K, Koike H, et al.: Age of onset influences clinical features of chronic inflammatory demeylinating polyneuropathy. J Neurol Sci 2001, 184:57–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Hughes R, Bensa S, Willison H, et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195–201.PubMedCrossRefGoogle Scholar
  11. 11.
    The Neuropathy Association, Medical Advisory Committee: Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Periph Nervous Syst 2003, 8:282–284.CrossRefGoogle Scholar
  12. 12.
    Nicolas G, Miasonobe T, Le Forestier N, et al.: Proposed revised electrophysiological criteria for chronic inflammatory demeylinating polyradiculoneuropathy. Ann Neurol 2002, 25:26–30.Google Scholar
  13. 13.
    Thiasetthawatkul P, Logogian EL, Herrmann DN: Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 2002, 59:1526–1532.Google Scholar
  14. 14.
    Magda P, Latov N, Brannagan TH, et al.: Comparison of the electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2003, 60:1755–1759.PubMedCrossRefGoogle Scholar
  15. 15.
    Saperstein DS, Barohn RJ: Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy. Curr Neurol Neurosci Rep 2003, 3:57–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Koller H, Kieseier BC, Jander S, Hartung HP: Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005, 352:1343–1356.PubMedCrossRefGoogle Scholar
  17. 17.
    Nobile-Orazio E: Multifocal motor neuropathy. J Neuroimmunol 2001, 115:4–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Saperstein DS, Amato AA, Wolfe GI, et al.: Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999, 22:560–566.PubMedCrossRefGoogle Scholar
  19. 19.
    Kuwabara S, Misawa S, Kanai K, et al.: Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006, 66:105–107.PubMedCrossRefGoogle Scholar
  20. 20.
    Dyck PJ, Engelstad J, Dispenzieri A: Vascular endothelial growth factor and POEMS. Neurology 2006, 66:10–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Carpo M, Allaria S, Scarlato G, Nobile-Orazio E: Marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy. Neurology 1999, 53:2206–2207.PubMedGoogle Scholar
  22. 22.
    Brannagan TH: Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology 2002, 59:S33–S40.PubMedCrossRefGoogle Scholar
  23. 23.
    Van Doorn PA, Brand A, Strengers PF, et al.: High-dose immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo controlled, crossover study. Neuology 1990, 40:209–212.Google Scholar
  24. 24.
    Hahn AF, Bolton CF, Zochodne D, Faesby TE: Intravenous immunoglobulin treatment in chronic inflammatory polyneuropathy. A double-blind, placebo controlled, cross-over study. Brain 1996, 119:1067–1077.PubMedCrossRefGoogle Scholar
  25. 25.
    Mendell JR, Barohn RJ, Freimer ML, et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56:445–449.PubMedGoogle Scholar
  26. 26.
    Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055–1066.PubMedCrossRefGoogle Scholar
  27. 27.
    Dyck PJ, O’Brien PC, Ovaitt KF, et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136–141.PubMedCrossRefGoogle Scholar
  28. 28.
    Dyck PJ, Litchy WJ, Kratz KM, et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994, 36:838–845.PubMedCrossRefGoogle Scholar
  29. 29.
    Pachner AR: Immunosuppressive therapy: targeting the autoantigen in neurologic disease. Adv Neurol 1997, 4:3–8.Google Scholar
  30. 30.
    McCombe PA, Pollard JD, McLeod JG: Chonic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiologic study of 92 cases. Brain 1987, 110:1617–1630.PubMedCrossRefGoogle Scholar
  31. 31.
    Barohn RJ, Kissel JT, Warmolts JR, Mendell JR: Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course and recommendations for diagnostic criteria. Arch Neurol 1989, 46:878–884.PubMedGoogle Scholar
  32. 32.
    Mehndiratta MM, Hughes RA: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002, CD002062.Google Scholar
  33. 33.
    Veenstra DL, Best JH, Hornberger J, et al.: Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999, 33:829–839.PubMedGoogle Scholar
  34. 34.
    Zonana-Nacach A, Barr SG, Magder LS, Petri M: Damage in systemic lupus erythematous and its association with corticosteroids. Arthritis Rheum 2000, 43:1801–1808.PubMedCrossRefGoogle Scholar
  35. 35.
    Ropper AH: Current treatments of CIDP. Neurology 2003, 60(Suppl 3):S16–S22.PubMedGoogle Scholar
  36. 36.
    van Schaik IN, Winer JB, de Haan R, Vermeulen M: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002, CD001797.Google Scholar
  37. 37.
    Federico P, Zochodne DW, Hahn AF, et al.: Multifocal motor neuropathy improved by IVIg. Randomized double-blind, placebo-controlled study. Neurology 2000, 55:12 56–12 62.Google Scholar
  38. 38.
    Leger JM, Chassande B, Musset L, et al.: Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001, 124:145–153.PubMedCrossRefGoogle Scholar
  39. 39.
    Azulay JP, Blin O, Pouget J, et al.: Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994, 44:429–432.PubMedGoogle Scholar
  40. 40.
    van den Berg LH, Kerkhoff H, Oey PL, et al.: Treatment of multifocal motor neuropathy with high dose intravenous immuno-globins: a double-blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995, 59:248–252.PubMedGoogle Scholar
  41. 41.
    Koski CL: Therapy of CIDP and related immune-mediated neuropathies. Neurology 2002, 59(Suppl 6):S22–S27.PubMedGoogle Scholar
  42. 42.
    Dalakas MC, Quarles RH, Farrer RG, et al.: A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IGM gammopathy. Ann Neurol 1996, 40:792–795.PubMedCrossRefGoogle Scholar
  43. 43.
    Comi G, Roveri L, Swan A, et al.: A randomized controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002, 249:1370–1377.PubMedCrossRefGoogle Scholar
  44. 44.
    Nobile-Orazio E, Meucci N, Baldini L, et al.: Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000, 123:710–717.PubMedCrossRefGoogle Scholar
  45. 45.
    Brannagan TH, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996, 47:674–677.PubMedGoogle Scholar
  46. 46.
    Vucic S, Black KR, Chong PS, Cros D: Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004, 63:1264–1269.PubMedGoogle Scholar
  47. 47.
    National Institutes of Health Consensus Conference: Intravenous immune globulin: prevention and treatment of disease. JAMA 1990, 264:3189–3193.Google Scholar
  48. 48.
    Center of Disease Control and Prevention: Renal insufficiency and failure associated with immune globulin intravenous therapy — United States, 1985–1998. Morb Mortal Wkly Rep 1999, 35:231–233.Google Scholar
  49. 49.
    Mehndiratta MM, Hughes RA, Agarwal P: Plasma exchange for chronic inflammatory polyradiculoneuropathy. Cochrane Database Syst Rev 2004, CD003906.Google Scholar
  50. 50.
    Heininger K, Liebert UG, Toyka KV, et al.: Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G. J Neurol Sci 1984, 66:1–14.PubMedCrossRefGoogle Scholar
  51. 51.
    Dyck PJ, Daube J, O’Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461–465.PubMedCrossRefGoogle Scholar
  52. 52.
    Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055–1066.PubMedCrossRefGoogle Scholar
  53. 53.
    Blume G, Pestronk A, Goodnough LT: Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plamsa exchange and IV cyclophosphamide. Neurology 1995, 45:1577–1580.PubMedGoogle Scholar
  54. 54.
    Carpo M, Cappellari A, Mora G, et al.: Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998, 50:1480–1482.PubMedGoogle Scholar
  55. 55.
    Hughes RA, Bouche P, Cornblath DR, et al.: European Federation of Neurologic Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurologic Societies and the Peripheral Nerve Society. Eur J Neurol 2006, 13:326–332.PubMedCrossRefGoogle Scholar
  56. 56.
    Barrnett MH, Pollard JD, Davies L, McLeod JG: Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998, 21:454–460.CrossRefGoogle Scholar
  57. 57.
    Mahattanakul W, Crawford TO, Griffin JW, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporine-A. J Neurol Neurosurg Psychiatry 1996, 60:185–187.PubMedGoogle Scholar
  58. 58.
    Matsuda M, Hoshi K, Gono T, et al.: Cyclosporin A in treatment of of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004, 224:29–35.PubMedCrossRefGoogle Scholar
  59. 59.
    Ahlmen J, Anderson O, Hallgren G, Peilot B: Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998, 30:4194.PubMedCrossRefGoogle Scholar
  60. 60.
    Good JL, Chehrenama M, Mayer RF, Koski CL: Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 51:1735–1738.PubMedGoogle Scholar
  61. 61.
    Brannagan TH, Pradhan A, Heiman-Patterson T, et al.: High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002, 58:1856–1858.PubMedGoogle Scholar
  62. 62.
    Pentland B: Azathioprine in chronic relapsing idiopathic polyneuropathy. Postgrad Med J 1980, 56:734–735.PubMedCrossRefGoogle Scholar
  63. 63.
    Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715–717.PubMedGoogle Scholar
  64. 64.
    Dyck PJ, O’Brien P, Swanson C, et al.: Combined azathioprine and prednisone in chronic inflammatory-demyelinating ployneuropathy. Neurology 1985, 35:1173–1176.PubMedGoogle Scholar
  65. 65.
    Hughes RA, Swan AV, van Doorn PA: Cytotoxic drugs and interferons for chronic inflammatory polyradiculoneuropathy. Cochrane Database Syst Rev 2004, CD003280.Google Scholar
  66. 66.
    Ho S, Clipstone N, Timmermann L, et al.: The mechanism of action of cyclosporine A and FK506. Clin Immunol Immunopathol 1996, 80:S40–45.PubMedCrossRefGoogle Scholar
  67. 67.
    Umapathi T, Hughes RA, Nobile-Orazio E, Léger JM: Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2005, CD003217.Google Scholar
  68. 68.
    Brock N, Stekar J, Pohl J, et al.: Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sulfosfamide. Arzneimittelforschung 1979, 29:659–661.PubMedGoogle Scholar
  69. 69.
    Gladstone DE, Prestrud AA, Brannagan TH: High-dose cyclophosphamide results in long-term disease remission with restoration of normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005, 10:11–16.PubMedCrossRefGoogle Scholar
  70. 70.
    Bouchard C, Lacroix C, Plante V, et al.: Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 2005, 5:242–245.Google Scholar
  71. 71.
    Brannagan TH, Aleadini A, Gladstone DE: High-dose cyclophosphamide without stem-cell rescue for refractory multifocal motor neuropathy. Muscle Nerve 2006, In press.Google Scholar
  72. 72.
    Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA: Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol 1999, 230(Suppl):111–115.CrossRefGoogle Scholar
  73. 73.
    Dalakas MC, Engel WK: Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981, 9:S134–S145.CrossRefGoogle Scholar
  74. 74.
    McCombe PA, Pollard JD, McLeod JG: Chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological study of 92 cases. Brain 1987, 110:1617–1630.PubMedCrossRefGoogle Scholar
  75. 75.
    Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47(2–3):85–118.PubMedCrossRefGoogle Scholar
  76. 76.
    Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715–717.PubMedGoogle Scholar
  77. 77.
    Benedetti L, Grandis M, Nobbio L: Mycophenylate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004, 29:748–749.PubMedCrossRefGoogle Scholar
  78. 78.
    Hadden RD, Sharrack B, Bensa S, et al.: Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999, 53:57–61.PubMedGoogle Scholar
  79. 79.
    Grillo-Lopez AJ: Rituximab: an insider’s historical perspective. Semin Oncol 2000, 276(6 Suppl 12):9–16.Google Scholar
  80. 80.
    Briani C, Zara G, Zambello R, et al.: Rituximab-responsive CIDP. Eur J Neurol 2004, 11:788.PubMedCrossRefGoogle Scholar
  81. 81.
    Knecht H, Blumberger M, Tobon A, Steck A: Sustained remission of CIDP associated with Evans syndrome. Neurology 2004, 63:730–732.PubMedGoogle Scholar
  82. 82.
    Bodley-Scott DD: Chronic inflammatory demyelinating polyradiculoneuropathy responding to rituximab. Practical Neurol 2005, 5:242–245.CrossRefGoogle Scholar
  83. 83.
    Latov N, Sherman WH, Vlahides G: Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with Rituxan. Neurology 1999, 52:A551.Google Scholar
  84. 84.
    Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion therapy using Rituximab. Neurology 1999, 52:1701–1704.PubMedGoogle Scholar
  85. 85.
    Pestronk A, Florence J, Miller T, et al.: Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003, 74:485–489.PubMedCrossRefGoogle Scholar
  86. 86.
    Kilidireas C, Anagnostopoulus A, Karandreas N, et al.: Rituximab therapy in monoclonal IgM-related neuropathies. Leuk Lymphoma 2006, 47:859–864.PubMedCrossRefGoogle Scholar
  87. 87.
    Hirst C, Raasch S, LLewelyn G, Robertson N: Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 2006, 77:800–802.PubMedCrossRefGoogle Scholar
  88. 88.
    Khanna D, McMahon M, Furst DE: Safety of tumour necrosis factor-alpha antagonists. Drug Safety 2004, 27:307–324.PubMedCrossRefGoogle Scholar
  89. 89.
    Chin RL, Sherman WH, Sander HW, et al.: Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003, 310:19–21.CrossRefGoogle Scholar
  90. 90.
    Choudhary PP, Thompson N, Hughes RA: Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995, 242:252–253.PubMedCrossRefGoogle Scholar
  91. 91.
    Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al.: Interferon-beta 1a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999, 53:1364–1365.PubMedGoogle Scholar
  92. 92.
    Radziwill AJ, Kuntzer T, Fuhr P, Steck AJ: Long term follow up in chronic inflammatory demyelinating polyneuropathy (CIDP) under interferon beta-1a (IFN-b1a) and intravenous immunoglobulin (IVIg). J Neurol Neurosurg Psychiatry 2001, 70:273.Google Scholar
  93. 93.
    Vallet JM, Hahn AF, Léger JM, et al.: Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003, 60(Suppl 8):23–28.Google Scholar
  94. 94.
    Gorson KC, Ropper AH, Clark BD, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998, 50:84–87.PubMedGoogle Scholar
  95. 95.
    Pavesi JW, Cattaneo L, Marbini A, et al.: Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 2002, 249:777–779.PubMedCrossRefGoogle Scholar
  96. 96.
    McCrone P, Chisholm D, Knapp M, et al.: Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003, 6:687–694.CrossRefGoogle Scholar
  97. 97.
    Gorson KC, Amato AA, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without monoclonal gammopathy. Neurology 1997, 48:321–328.PubMedGoogle Scholar
  98. 98.
    De Sousa EA, Brannagan TH: Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 2006, 8:91–103.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Department of NeurologyWeill Medical College of Cornell University, Peripheral Neuropathy CenterNew YorkUSA

Personalised recommendations